二重特異性T細胞誘導抗体
↑ Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin; Hasenburg, Annette; Seggewiss-Bernhardt, Ruth; Ritter, Barbara; Rautenberg, Beate; Atanackovic, Djordje et al. (2018). “A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors”. Oncoimmunology 7 (8): e1450710. doi:10.1080/2162402X.2018.1450710. ISSN 2162-4011. PMC 6136859. PMID 30221040. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136859/.
↑ Kischel, R (2008). “Characterization in primates of MCSP- and CD33-specific human BiTE antibodies for treatment of Melanoma and AML”. Proc Am Assoc Cancer Res 99: Abs 2404. オリジナルの2011-07-19時点におけるアーカイブ。.